CTI BioPharma

215 articles with CTI BioPharma

• CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 21, 2023

  3/21/2023

  CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to four new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.

• CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6, 2023

  3/6/2023

  CTI BioPharma Corp. today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to five new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan.

• CTI BioPharma To Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Monday, March 6, 2023

  2/23/2023

  CTI BioPharma Corp. today announced that its fourth quarter and full year 2022 financial results will be reported on Monday, March 6, 2023, after the close of the financial market.

• CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 08, 2023

  2/8/2023

  CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to three new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.

• CTI BioPharma to Participate in Upcoming Investor Conferences in February 2023

  2/2/2023

  CTI BioPharma Corp. (Nasdaq: CTIC) today announced that senior leadership will participate in a Fireside Chat at the following investor conferences in February 2023.

• CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 25, 2023

  1/25/2023

  CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employee's acceptance of employment with the company.

• CTI BioPharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/5/2023

  CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.

• CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 20, 2022

  12/20/2022

  CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to three new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.

• CTI BioPharma Presents New Anemia Benefit Data from Pacritinib Program at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition

  12/11/2022

  CTI BioPharma Corp. announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64th American Society of Hematology Annual Meeting and Exposition, taking place in New Orleans, Louisiana and virtually December 10-13, 2022.

• CTI BioPharma to Present at the JMP Securities Hematology and Oncology Summit

  11/30/2022

  CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit at 3:00 p.m. ET.

• CTI BioPharma to Present at Upcoming November 2022 Conferences

  11/8/2022

  CTI BioPharma Corp. announced that management will provide a corporate overview at two upcoming investor conferences in New York and London.

• CTI BioPharma Reports Third Quarter 2022 Financial Results

  11/7/2022

  CTI BioPharma Corp. reported its financial results for the third quarter ended September 30, 2022.

• CTI BioPharma to Report Third Quarter 2022 Financial Results on November 7, 2022

  10/27/2022

  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2022 financial results on Monday, November 7, 2022, after the close of the U.S. financial markets.

• CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 17, 2022

  10/17/2022

  CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.

• CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 22, 2022

  9/22/2022

  CTI BioPharma Corp. announced the grant of equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.

• CTI BioPharma Announces Presentation of New Anemia Benefit Data from Pacritinib Program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting

  9/21/2022

  CTI BioPharma Corp. (NASDAQ: CTIC) today announced two poster presentations from the Company's pacritinib program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting, to be held in Houston, Texas and virtually September 28 – October 1, 2022.

• CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 22, 2022

  8/22/2022

  CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.

• CTI BioPharma to Report Second Quarter 2022 Financial Results on August 8, 2022

  8/1/2022

  CTI BioPharma Corp. ( CTI BioPharma ) ( NASDAQ : CTIC ) today announced that management plans to report its second quarter 2022 financial results on Monday, August 8, 2022, after the close of the U.S. financial markets.

• CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 14, 2022

  6/14/2022

  CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employee's acceptance of employment with the company.

• CTI BioPharma Presents Pivotal Data from Pacritinib Program at the European Hematology Association (EHA) 2022 Congress

  6/10/2022

  CTI BioPharma Corp. (Nasdaq: CTIC) today announced two scientific poster presentations from the Company's pacritinib clinical program at the European Hematology Association (EHA) 2022 Congress, being held in Vienna, Austria , June 9-12, 2022.